Fulcrum Therapeutics Inc
FULC
Market Cap$369.76M
Close$
$0.02
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $369.76 Million |
|---|---|
| Enterprise Value | $335.69 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.17 |
| Beta | 2.42 |
| Outstanding Shares | 62,479,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -839.18 |
|---|---|
| PEG | 2446.96 |
| Price to Sales | 6.85 |
| Price to Book Ratio | 2.28 |
| Enterprise Value to Revenue | 4.2 |
| Enterprise Value to EBIT | -26.93 |
| Enterprise Value to Net Income | -659 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Fulcrum Therapeutics Inc
73 employeesFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies dru...